Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CUBIC trial of rituximab-based immunoglobulin reduction in CIDP
ACTRN12623001336673Phase 2Not yet recruiting
- Sponsor
- Western Sydney Local Health District
- Start
- Aug 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of rituximab and immune globulin in chronic inflammatory demyelinating polyneuropathy (CIDP), sponsored by Western Sydney Local Health District. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
rituximabimmune globulin
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on ACTRN12623001336673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12623001336673.